获取途径

作者

Liu, Chao Wang, Jing An, Ning Li, Aijie Yan, Weiwei Zhu, Hui Yu, Jinming

作者单位

Department of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, 100071, China Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China Weifang Medical University, Weifang, Shandong, 261053, China Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China

刊名

Journal of Translational Medicine

年份

2019

卷号

Vol.17 No.1

ISSN

1479-5876

摘要

Background: Noninvasive prognostic biomarkers are needed for advanced non-small cell lung cancer patients with different histological types to identify cases with poor survival. Here, we investigated the prognostic values of peripheral CD8+CD28+ T cells and CD8+CD28-T cells in advanced NSCLC patients treated with chemotherapy and the impact of histological type on them. Methods: Of 232 registered advanced NSCLC patients, 101 treatment-naïve individuals were eligible and included in our study. F...更多

Background: Noninvasive prognostic biomarkers are needed for advanced non-small cell lung cancer patients with different histological types to identify cases with poor survival. Here, we investigated the prognostic values of peripheral CD8+CD28+ T cells and CD8+CD28-T cells in advanced NSCLC patients treated with chemotherapy and the impact of histological type on them. Methods: Of 232 registered advanced NSCLC patients, 101 treatment-naïve individuals were eligible and included in our study. Flow cytometry was used to evaluate CD8+CD28+ T cells, CD8+CD28-T cells, CD4+ CD25hi T cells, B cells, natural killer cells, γδT cells, and natural killer T cells in patients' peripheral blood. Results: The median follow-up time was 13.6 months. Fifty-nine patients died by the end of our study. Fifty-three of the 101 advanced NSCLC cases selected for our study were adenocarcinomas , and 48 were squamous cell carcinomas . Multivariate analyses showed that increased levels of CD8+CD28+ T cells independently predicted favorable overall survival [hazard ratio : 0.51, 95% confidence interval 0.30-0.89, P = 0.021] and progression-free survival in ADs, but the prediction in SCCs was not statistically significant. In contrast, high levels of CD8+CD28-T cells independently predicted unfavorable OS and PFS in SCCs, but the prediction in ADs was not statistically significant. ADs had higher levels of CD4+CD25hi T cells and CD8+CD28-T cells and lower NK cells than SCCs. Conclusions: Our findings uncovered the prognostic values of peripheral CD8+CD28+ T cells and CD8+CD28-T cells in advanced NSCLC patients treated with chemotherapy, which could help to identify patients with poor outcomes and refine treatment strategies.收起

文献类型

期刊

浏览量

7